By Evan Weinberger ( December 14, 2010, 2:09 PM EST) -- Mylan Pharmaceuticals Inc. has asked the U.S. Supreme Court to review its loss in a patent infringement suit over generic hypertension drugs, claiming that a federal appeals court has established a "troubling pattern" of relying on a rigid test for obviousness in generics cases....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.